Cerebrolysin

A complex mixture of low molecular weight neuropeptides and amino acids derived from porcine brain protein. It crosses the blood-brain barrier and mimics natural neurotrophic factors.

Promotes neuroplasticity, neurogenesis and neuroprotection. Mimics the effects of BDNF, NGF and CNTF, reduces neuronal apoptosis, and is anti-inflammatory in the CNS.

Cerebrolysin is used clinically for stroke recovery and cognitive decline in over 50 countries. It essentially provides the brain with the building blocks and signals it needs to repair and maintain itself.

• Cognitive assessment scales
• Infarct volume and recovery scoring
• Neurotrophic factor expression
• Neuronal apoptosis markers
• CNS inflammatory markers

• Stroke recovery
• Alzheimers disease
• Vascular dementia
• Traumatic brain injury
• Cognitive enhancement in healthy subjects

Developed in Austria by Ever Pharma from enzymatically processed porcine brain protein, and approved for clinical neurological use in more than 50 countries.

Men and women 40 plus focused on cognitive decline prevention, neuroprotection, post-stroke recovery and memory support.

• Supplied as a ready solution rather than lyophilised powder.
• Store refrigerated and protect from light.
• Do not mix with incompatible amino acid solutions.
• Protocols in literature use cyclical courses.
• Inspect solution clarity before research use.

• A mixture rather than a single peptide, batch consistency matters.
• Porcine derived, relevant for some research contexts.
• Extensive European and Asian clinical literature.
• Cyclical course design is standard in published protocols.